Rhythm Pharmaceuticals, Inc. RYTM Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 89.7%0.0pp | 89.7%+1.7pp | 88%-3.0pp | 91%+10.0pp | |
| Operating margin | -101.2%+103pp | -204%+34.1pp | -238.1%+520pp | -757.9%+4,634pp | |
| Net margin | -103.6%+96.7pp | -200.2%+38.3pp | -238.5%+528pp | -766.2%+1,441pp | |
| Returns | |||||
| Return on equity | -244.5%+27.7pp | -272.1%-187pp | -85.1%-19.0pp | -66.1%-35.2pp | |
| Return on invested capital | -157.9%+43.7pp | -201.6%-97.9pp | -103.7%-6.3pp | -97.4%+15.7pp | |
| Efficiency | |||||
| Asset turnover | 0.4×+0.1× | 0.4×+0.1× | 0.2×+0.2× | 0.1×+0.1× | |
| Liquidity | |||||
| Current ratio | 4.4×+1.2× | 3.2×-2.3× | 5.6×-3.3× | 8.9×+1.8× | |
| Leverage | |||||
| Debt-to-equity | 0.8×-4.4× | 5.2×+4.6× | 0.6×+0.6× | 0×0.0× | |
| Per Share | |||||
| Book value per share | $2.14+501% | $0.36-87.9% | $2.94-41.9% | $5.07-11.5% | |
| Valuation | |||||
| Market capitalization | $7.14B+108% | $3.44B+26.4% | $2.72B+65.9% | $1.64B+227% | |
| Price / sales | 37.6×+11.2× | 26.4×-8.7× | 35.2×-34.3× | 69.4×-89.6× | |
| Price / book | 51.4×-107× | 158.3×+142× | 16×+9.8× | 6.2×+4.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Rhythm Pharmaceuticals, Inc.'s profit margins?
- Rhythm Pharmaceuticals, Inc. (RYTM) runs a 89.4% gross margin and a -90.9% operating margin, with a -93.3% net margin.
- Where do Rhythm Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Rhythm Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
